Uterine Fibroids

FDA approves ExAblate 2000 system as noninvasive surgery for uterine fibroids

Published in Women's Health Weekly, November 25th, 2004

InSightec reported that the U.S. Food and Drug Administration (FDA) has awarded premarket approval (PMA) to the company's ExAblate 2000 system for noninvasive surgery for symptomatic uterine fibroids.

Elbit Medical Imaging, Ltd., (EMITF) and General Electric (GE) are significant shareholders in InSightec.

According to the U.S. National Institutes of Health (NIH), at least 25% of women suffer from uterine fibroids.

"Many women with fibroids continue to suffer with their symptoms rather than undergo treatment out of concern for the side effects of existing therapies. ExAblate 2000 gives women an important new choice to help reduce...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry